Back to Search

PETER LENEHAN, MD

MD

General Practice Physician

NPI: 1306182951Individual

Specialties, Licenses & Credentials

General Practice PhysicianPrimary

General Practice

Code: 208D00000X

4301065701(MI)

Research & Publications (18)

The natural history of wheat allergy.
PMID 19492663·Ann Allergy Asthma Immunol·2009
8-other
Multicenter, randomized, phase II trial of CI-1033, an irreversible pan-ERBB inhibitor, for previously treated advanced non small-cell lung cancer.
PMID 17761977·J Clin Oncol·2007
3-trial
Phase I clinical and pharmacodynamic evaluation of oral CI-1033 in patients with refractory cancer.
PMID 17505003·Clin Cancer Res·2007
3-trial
Intestinal mucosa remodeling by recombinant human epidermal growth factor(1-48) in neonates with severe necrotizing enterocolitis.
PMID 17336181·J Pediatr Surg·2007
2-rct
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
PMID 17409987·J Thorac Oncol·2006
3-trial
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
PMID 16899614·Clin Cancer Res·2006
3-trial
Cervical screening history in patients with early stage carcinoma of the cervix.
PMID 16892918·Ir Med J·2006
8-other
A phase I clinical and pharmacokinetic study of oral CI-1033 in combination with docetaxel in patients with advanced solid tumors.
PMID 16857802·Clin Cancer Res·2006
3-trial
The use of genetic programming in the analysis of quantitative gene expression profiles for identification of nodal status in bladder cancer.
PMID 16780590·BMC Cancer·2006
4-observational
Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer.
PMID 16110019·J Clin Oncol·2005
3-trial
Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer.
PMID 15897585·Clin Cancer Res·2005
3-trial
Administration of CI-1033, an irreversible pan-erbB tyrosine kinase inhibitor, is feasible on a 7-day on, 7-day off schedule: a phase I pharmacokinetic and food effect study.
PMID 15534081·Clin Cancer Res·2004
3-trial
Bowel evisceration.
PMID 15055918·Ir Med J·2004
5-case
CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer.
PMID 14613028·Semin Oncol·2003
6-review
Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer.
PMID 12138393·Semin Oncol·2002
6-review
Phase 1 drug interaction study of suramin and warfarin in patients with prostate cancer.
PMID 11319293·Am J Clin Oncol·2001
3-trial
Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival.
PMID 11230472·J Clin Oncol·2001
3-trial
Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone.
PMID 10735891·J Clin Oncol·2000
3-trial

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Address
1187 PIERCE RD
CHELSEA, MI 48118

Location

Practice Location

1187 PIERCE RD, CHELSEA, MI
(734) 475-1033

Quick Facts

NPI
1306182951
Entity Type
Individual
Gender
Male
Medicare
Not confirmed
Specialties
1
Locations
1
Publications
18

Are you this provider?

Claim Your Profile